Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 13, 2023 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
March 31, 2023 07:00 ET
|
Cabaletta Bio
– IND application cleared within 6 months of in-licensing CABA-201 binder – – CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design,...
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 07:00 ET
|
Cabaletta Bio
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical...
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces $35 Million Offering
December 08, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the...
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
October 11, 2022 07:00 ET
|
Cabaletta Bio
– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases – – CABA-201...